Claims for Patent: 5,610,043

Summary for Patent: 5,610,043

Title:	Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
Abstract:	Immortalized non-tumorigenic or tumorigenic human prostatic epithelial and fibroblast cell lines and derivatives thereof, containing DNA of a hybrid virus between adenovirus 12 and simian virus 40. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.
Inventor(s):	Webber; Mukta M. (Eagle, MI), Rhim; Johng S. (Potomac, MD)
Assignee:	The United States of America as represented by the Department of Health (Washington, DC)
Application Number:	08/234,981
Patent Claims:	1. An immortalized adult human normal prostatic epithelial or fibroblast cell derived cell line free of other cell lines and containing DNA of adenovirus and simian virus 40 as a hybrid virus, the cell line having the identifying characteristics of the prostatic epithelial or fibroblast cell without the hybrid virus in addition to being immortalized by the hybrid virus. 2. The cell line of claim 1 wherein the simian virus 40 is deposited as ATCC VR-239. 3. The cell line of claim 1 wherein the adenovirus is adenovirus 12 deposited as ATCC VR-863. 4. The cell line of claim 1 wherein the adenovirus is adenovirus 12 and the simian virus 40 is deposited as ATCC VR-863 and VR-239, respectively. 5. The cell line of claim 1 which produces prostate specific antigen. 6. A cell line deposited as ATCC CRL 11611. 7. An immortalized human prostatic epithelial cell line wherein the cell line has the phenotypic characteristics comprising: cytokeratins 8/18 positive, desmin negative, Factor VIII negative, contact inhibited, anchorage dependent, androgen responsive, plasminogen activator secretion normal, collagenase secretion normal, is non-tumorigenic, produces prostate specific antigen and contains a hybrid virus of adenovirus and simian virus 40. 8. The cell line of claim 7 wherein the simian virus 40 is deposited as ATCC VR-239 and the adenovirus is adenovirus 12 deposited as ATCC VR-863. 9. A kit for screening a carcinogenic, chemotherapeutic, chemopreventive, anti-invasive, anti-metastatic or anti-angiogenic agent comprising an immortalized adult human prostatic epithelial cell derived cell line containing DNA of adenovirus and simian virus 40 as a hybrid virus, the cell line having the identifying characteristics of the prostatic epithelial cell without the hybrid virus in addition to being immortalized by the hybrid virus. 10. The kit according to claim 9 wherein the immortalized cell line is immortalized using simian virus 40 deposited as ATCC VR-239 and adenovirus 12 deposited as ATCC VR-863. 11. The kit according to claim 9 wherein the immortalized cell line is non-tumorigenic. 12. The kit according to claim 9 wherein the immortalized cell line is made tumorigenic after additional transformation by infection with oncogenic viruses, activation of oncogenes, transfection with activated oncogenes, loss of suppressor genes, or chemical exposure or radiation. 13. The kit of claim 9 wherein the cell line produces prostate specific antigen. 14. A method for producing an immortalized adult human normal prostatic epithelial or fibroblast cell derived cell line which comprises: (a) providing non-malignant human prostatic epithelial or fibroblast cells in a medium; and (b) infecting the human prostatic epithelial or fibroblast cells in the medium with DNA from adenovirus and simian virus 40 as a hybrid virus to thereby immortalize the cells with the hybrid virus to produce the cell line, wherein the cell line has the identifying characteristics of the prostatic epithelial or fibroblast cell without the hybrid virus in addition to being immortalized by the hybrid virus. 15. The method of claim 14 wherein the simian virus 40 is deposited as ATCC VR-239. 16. The method of claim 14 wherein the adenovirus is adenovirus 12 deposited as ATCC VR-863. 17. The method of claim 14 wherein the adenovirus is adenovirus 12 and the simian virus 40 is deposited as ATCC VR-863 and VR-239, respectively. 18. The method of claim 14 wherein the immortalized cell line deposited as ATCC CRL 11611. 19. The method of claim 14 wherein after the infecting in step (b) the cell line is subjected to multiple cloning to select a non-virus producing cell line in a serum free, chemically defined medium. 20. The method of claim 19 wherein the medium contains pituitary extract and epidermal growth factor. 21. The method of claim 14 wherein the cell line produces prostate specific antigen.

Details for Patent 5,610,043

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-02-26